Results 261 to 270 of about 243,764 (341)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Managing Bipolar Disorder With Aripiprazole Once Monthly: From Symptom Stabilization to Functional Recovery. [PDF]

Psychiatry Investig
Yang HR, Jung S, Moon J, Lee MY, Moon S, Shin DW, Cho SJ.   +6 more
europepmc   +1 more source

The use of different types of networks, alone and in combination, for drug target identification

British Journal of Pharmacology, EarlyView.
Current therapeutic approaches often focus on targeting clinical symptoms or peripheral phenotypes rather than the underlying molecular mechanisms, or endophenotypes, that drive diseases. While symptom‐based drugs can alleviate discomfort, they do not necessarily alter disease progression and may overlook opportunities for prevention or early ...
Paolo Parini
wiley   +1 more source

Effect of body-oriented psychological therapy on negative symptoms in schizophrenia: a randomized controlled trial [PDF]

, 2006
Priebe, S, Rohricht, F
core   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Monotherapy Versus Combination Therapy in Agitation Management in the Intensive Care Unit: A Narrative Review. [PDF]

Cureus
Kirishnaventhan R, Corso G, Patel S, Batakanwa S.   +3 more
europepmc   +1 more source

Choroid plexus volume enlargement in first-episode antipsychotic-naïve schizophrenia [PDF]

Jiaxin Zeng, Tianwei Zhang, Biqiu Tang, Siyi Li, Yao Li, Jeffrey R. Bishop, John A. Sweeney, Zhenlin Li, Changjian Qiu, Shi Gu, Qiyong Gong, Wenjing Zhang, Su Lui   +12 more
openalex   +1 more source

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source

Ketogenic Diet as Protection for Deprescribing Antipsychotics. [PDF]

Schizophr Bull
Schlimme JE.
europepmc   +1 more source

Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications

Molecular Psychiatry, 2014
Brisa Fernandes, J. Steiner, M. Berk, M. Molendijk, A. González-Pinto, C. Turck, P. Nardin, C. Gonçalves   +7 more
semanticscholar   +1 more source